September 2022 PMID 36050763

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

Michael A Nauck, David A D'Alessio

Full text PDF Download social card

Mentions

Peak: 40 in Sep 2022

across 3 sources since Sep 2022

Extended reach

468,825

potential audience

Total likes

155

Video views

2,393

Mentions per month

Sep 2022 – Jun 2025

Where it's discussed

X / Twitter44 posts
News11 articles
YouTube2 videos

AI synopsis

What people are saying

The collective discussions show a strong interest in the mechanisms behind Tirzepatide, with many posts referencing studies and reviews about its effects on metabolic processes, such as satiety and cardiovascular safety. The tone varies from supportive to inquisitive, emphasizing the potential significance of this research in diabetes and obesity treatment.

AgreementModerate agreement

Many discussions acknowledge the promising results of Tirzepatide, especially its effectiveness in glycemic and weight control, indicating general support for the publication's findings.

InterestHigh interest

The posts demonstrate high curiosity, referencing complex mechanisms, clinical studies, and debates, showing strong engagement with the topic.

EngagementModerate engagement

Discussion participants delve into mechanisms, compare treatments, and cite specific studies, indicating active engagement beyond superficial reactions.

ImpactHigh impact

Given the focus on potential new treatments and ongoing debates about mechanisms and efficacy, these discussions suggest the publication could influence future research and clinical practices.

Abstract in brief

Tirzepatide is the first dual GIP and GLP1 receptor coagonist approved for treating type 2 diabetes, showing exceptional results in controlling blood sugar and reducing body weight in clinical trials.
The medication significantly lowered HbA1c levels (blood sugar measure) and caused notable weight loss, with many patients reaching normal blood sugar levels and losing more than 10% of their initial body weight, outperforming other treatments like semaglutide and basal insulin.
Side effects were similar to those of existing GLP1-based drugs, mainly nausea and gastrointestinal issues, but cardiovascular safety was confirmed, with no increased risk of major heart-related events over two years, and some data suggesting possible cardiovascular benefits.

Read the full abstract

All mentions

Understanding Intestinal Hormones and Insulin Secretion in Glucose Regulation

The video explores the role of intestinal secretions, including hormones like GLP1 and GIP, in regulating insulin secretion and glucose metabolism, highlighting recent research findings and mechanisms involved.

Доказательная нутрициология и фитнес · Jun 21, 2025 2,208 views

New Weight Loss Medication More Effective Than Ozempic for Diabetes Treatment

Ozempic's days are numbered. A new diabetes medication approved in Brazil, Mounjaro, surpasses Ozempic in weight loss, but what are its side effects and precautions? Learn essential information about this innovative…

Dica Médica · Oct 13, 2023 185 views

Biotech Jim

@JamesEKrause · X

@Lehi88 Confusion in the literature on GIP agonists vs antagonists in this arena. Early studies by Drucker/colleagues and others in KO mice are confusing /inconclusive due to adaptation and other factors. Any lit on GIP agonism vs antagonism? Besides this T work

Mar 8, 2023 · 13,173 followers View post →

Armand Domalewski

@ArmandDoma · X

@AlecStapp Here's one study: https://t.co/ay1yLIPiis

Mar 2, 2023 · 12 likes · 1 share · 84,134 followers View post →

Viet Le DMSc PA-C FACC FAHA HF-Cert

@VietHeartPA · X

Dec 9, 2022 · 4 likes · 9,790 followers View post →

Dr. David Ludwig

@davidludwigmd · X

@DanielJDrucker @bcorkey @Tellit007 The issue we've been debating (I think) is whether incretins have metabolic effects beyond (or driving) hunger. If it's a canard, then others seem to be having duck for dinner. (One of many reviews highlighting uncertainty about mechanisms) https://t.co/N7RK9esm9k https://t.co/7enMouyEnf

Oct 1, 2022 · 43,525 followers View post →

John Andraos

@AndraosJohn · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 12, 2022 · 20 shares · 14 followers View post →

Dr. Spencer Nadolsky

@DrNadolsky · X

@BevTchangMD Another cool review going over the possible satiety effects of GLP-1 versus GIP https://t.co/T1cSIAYGwP https://t.co/9Zyy895GwM

Sep 12, 2022 · 4 likes · 59,298 followers View post →

Miguel Turégano

@tureyedro · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 5, 2022 · 19 shares · 814 followers View post →

ASEMEVE

@asemeve · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 5, 2022 · 19 shares · 475 followers View post →

Manu Morales Sánchez

@Manugrillo2 · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 4, 2022 · 19 shares · 2,140 followers View post →

Semergen Extremadura

@SemergenEx · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 4, 2022 · 19 shares · 1,069 followers View post →

Eduard Centeno

@segol60 · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 4, 2022 · 19 shares · 409 followers View post →

Antonio Juárez

@tonojuarezjaj · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 77 followers View post →

Manuel Codas, MD, FACP ®

@ManucoMd · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 2,843 followers View post →

Ana Piera #JuntosEsMasFacil

@ana_apiecar · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 2,575 followers View post →

JORGE FERNANDEZ

@drjorfer · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 1,019 followers View post →

Carlos Maiorana

@MaioranaCarlos · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 347 followers View post →

María Ballesteros

@mdballesteros · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 4,800 followers View post →

Sandro Corigliano

@SandroCoriglia1 · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 63 followers View post →

Manuel Botana

@mbotana · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 3,721 followers View post →

Daniela R

@DannyRiosM · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 517 followers View post →

Rafael Vidal

@rafaendo · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 473 followers View post →

Mohgah Elsheikh

@DrMohgah · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 1,179 followers View post →

Esteban Jódar Gimeno

@estebanjodar · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 4,520 followers View post →

jose miguel borrachero

@correodiabetes · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 1,353 followers View post →

Judith López

@Judithendo · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 1,684 followers View post →

Raquel Faradji

@rfaradji · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 1,121 followers View post →

Dimitris Papamargaritis

@ri_tis · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 702 followers View post →

@bimal2378 · X

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction https://t.co/nv6NZ0YqGc

Sep 3, 2022 · 38 followers View post →

RONAK GANDHI

@drronakmgandhi · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 259 followers View post →

Dr. Shashank Joshi

@AskDrShashank · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 32,517 followers View post →

Oscar Moreno #

@moreno_perez_o · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 3,396 followers View post →

Elena del Olmo

@eledelolmo · X

RT @CristobMorales: https://t.co/sPqWyF4Ccg Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unm…

Sep 3, 2022 · 19 shares · 480 followers View post →

Cristobal Morales

@CristobMorales · X

Sep 3, 2022 · 39 likes · 19 shares · 17,083 followers View post →

Neil Floch MD

@NeilFlochMD · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 3, 2022 · 20 shares · 130,122 followers View post →

Yeongkeun Kwon

@ykwonmd · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 13 followers View post →

LUIS GERARDO RODRIGUEZ TORRES

@LUISGER91044166 · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 6 followers View post →

Mark Herman

@MarkHermanMD · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 626 followers View post →

Dr Mushtaq Ahmad

@center_weight · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 140 followers View post →

Samar Hafida,MD

@Samarhafida · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 605 followers View post →

Mike Kelly

@mikesbkelly · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 386 followers View post →

Rafael Radaeli

@rfradaeli · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 383 followers View post →

INTERNAL MEDICINE

@medicinterna · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 2,460 followers View post →

Alberto Dias Filho

@albertodiasf · X

RT @DanielJDrucker: A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 20 shares · 236 followers View post →

Daniel J Drucker

@DanielJDrucker · X

A comprehensive review of Tirzepatide #T2D from Nauck and D’Alessio https://t.co/Lp86KOR5wb https://t.co/9WHmtDDQLS

Sep 2, 2022 · 54 likes · 20 shares · 34,366 followers View post →

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Understanding Intestinal Hormones and Insulin Secretion in Glucose Regulation

New Weight Loss Medication More Effective Than Ozempic for Diabetes Treatment